We investigated the clinical effects of long term therapy of the Erythromycin derivatives, Erythromycin (EM), Clarithromycin (CAM) and Roxithromycin (RXM), for chronic paranasal sinusitis. Seventy-one children (younger than 15 years old) and 87 adults (older than 16) were divided in 2 groups based on the presence or absence of nasal allergy.
The patients without nasal allergy were divided into the following 3 groups; group-A was treated with EM derivative alone, group-B with EM derivative and S-carboxyl methyl cystein (SCMC) and grourp-C with SCMC alone. Patients with nasal allergy were treated with anti-allergic agent and EM derivative (goup-D) or with EM derivative only (group-E).
Each EM derivative was administered at half the level of the normal doses and each antiallergic agent was given at the normal doses every day for 12 weeks.
The following results were obtained;
1) The improvement rates of symptoms and rhinoscopic findings were 60% (group-A) and 75% (group-B) in children and 60% (group-A) and 52.9% (group-B) in adults respectively. No significant differencee in clinical effects was observed between children and adults in groups A and B.
2) In group-E, improvement rates were 44.4% in children and 100% in adults, a result that showed significant difference.
In 26 children with chronic sinusitis intermittently treated by the administration of EM or CAM for more than 2 years, 5 (63%) out of 8 patients with no nasal allergy showed improvement of symptoms after 4 month-treatment.
While improvement was observed in 15 (83%) out of 18 patients with nasal allergy after 8 month-treatment.
No remarkable side effects were noted in any group.
抄録全体を表示